Therefore, we preliminarily inferred that the effects of IL-33 on antitumoral T cell response might exceed its effects on immunosuppressive M2-like macrophages, resulting in a potent antitumor effect in CRC. The gene discussed is IL33; the disease is colorectal carcinoma.